Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and -resistant stages in the immunological diabetic process

Production of nitric oxide (NO) in nonobese diabetic islets of diabetic female mice is attributed to immunological diabetogenic events. Pharmacological function of the drug aminoguanidine, an inactivator of NO synthase during the diabetic process, is investigated. Inhibitory role of aminoguanidine is a function of inhibitor levels and quantity of spleen cells transported during the diabetic process. The action of the drug leads to a decline in the formation of NO, and postpones the onset of diabetes by three to eight days.